Savara’s Strategic Positioning and Financial Strength Drive Buy Rating Amid Anticipated Molbreevi Launch

Savara (SVRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $6.00 price target.

Andrew Fein has given his Buy rating due to a combination of factors surrounding Savara’s strategic positioning and financial outlook. The anticipated launch of Molbreevi, a novel therapy for autoimmune pulmonary alveolar proteinosis (aPAP), is a significant driver of this rating. The company has requested FDA priority review for Molbreevi, with a potential PDUFA date by the end of the year and a commercial launch planned for early 2026. Additionally, there is a planned submission for marketing authorization in Europe and the UK, which could broaden Molbreevi’s market footprint.
Another factor contributing to the Buy rating is Savara’s strong financial position, with a cash runway expected to last into the second half of 2027, comfortably surpassing the US launch timing. The positive results from the Phase 3 IMPALA-2 trial, demonstrating significant improvements in lung function and quality of life measures, further support the potential success of Molbreevi. The company’s goal to reach 1,000 aPAP patients at launch, along with high patient interest in the therapy, underscores the market opportunity. These elements collectively reinforce the optimism for Savara’s prospects and justify the Buy rating.

According to TipRanks, Fein is an analyst with an average return of -2.0% and a 38.95% success rate. Fein covers the Healthcare sector, focusing on stocks such as Insmed, Neurocrine, and Wave Life Sciences.

In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $9.00 price target.